Chlamydia trachomatis, once thought to be a virus but proved on the basis of its type of genetic material, possession of ribosomes, and mode of replication to be a very small intracellular energy parasitic bacterium with a genome of 660 x 106 daltons (11, 14, 15, 17) , has two known species. Both species, C. trachomatis and C. psittaci, share a unique developmental cycle which consists of the alternation of two chlamydial cell types: the elementary body (EB), which is adapted to extracellular conditions and reentry into a new host cell, and a reticulate body (RB) adapted to intracellular multiplication by means of binary fission (5, 8, 10, 11) .
It was first found by Sueltenfuss and Pollard (16) that C.
psittaci resembles viruses not only in its being an intracellular parasite but also in its susceptibility to crude interferon (IFN). Rothermel et al. (12) have shown that murine fibroblast IFN caused, in cell cultures, a reduction in the rate of C. trachomatis RB replication and in the number of C. trachomatis inclusion-bearing cells. Comparison between C. trachomatis and C. psittaci showed that murine fibroblast IFN (o and ,B) reduced the intracellular development of C. trachomatis by 90%, whereas C. psittaci growth was not affected in IFN-treated cells (2).
It has been reported that lymphokines induced by concanavalin A stimulation of mouse spleen cells from C. psittaciimmune animals suppress the growth of C. psittaci in a mouse fibroblast cell line. Anti-murine gamma IFN immunoglobulin neutralized the lymphokine-mediated inhibition of C. psittaci (3). Rothermel et al. have recently shown that partially purified human y-IFN induced human macrophages to restrict C. psittaci growth by 95% (13) .
We report here the results of our investigations on the effect of highly purified human gamma interferon on the development of C. trachomatis in HEp-2 cell cultures.
HEp-2 cells, originating from a human carcinoma of the larynx, were used to carry out the gamma IFN assays since they can be activated by human Titration of C. trachomatis was performed by the immunoperoxidase assay (6) modified for chlamydiae. C. trachomatis was titrated on MA-104 and HEp-2 cells. The cells were seeded at 5 x 104 per well in 96-microwell plates (Nunc). After 24 h, the medium was changed to growth medium. Twenty-four hours later, the cells were infected in triplicate with 10-fold dilutions of purified C. trachomatis. The progress of infection was followed by light microscopy; at 48 h postinfection, the cells were fixed with 100% ethanol, and an immunoperoxidase assay test (6) was performed. The staining appeared in the inclusions as well as on the membrane of C. trachomatis-infected cells.
Human gamma IFN from human lymphocytes, purified by means of monoclonal antibodies, was a gift from Inter-Yeda, Israel. It was kept at 4°C and diluted in distilled water to 50,000 IU/ml. Rabbit polyclonal antibodies (Abs) to human gamma (immune) IFN were purchased from Interferon Sciences Inc. This antiserum was assayed against and did not react with human alpha or beta IFN. Samples were prepared for electron microscopy as described by Biberfeld (1). Electron micrographs of the thin sections were taken with a Philips 201C Tem electron microscope.
C. trachomatis inhibition by -y-IFN was determined by a C. trachomatis titer reduction test (one-step growth experiment). HEp-2 cells were seeded in 96-microwell plates at 5 x 104 cells per well. The following day, medium was changed to cell growth medium containing IFN at various concentrations, and cells were incubated at 37°C for 24 h. Control cells were incubated with fresh growth medium. Purified C.
trachomatis was diluted in C. trachomatis growth medium without cycloheximide (12) . The HEp-2 cells were infected at a multiplicity of infection of 1 (9 that more than two cycles of intracellular development occurred; the control was nearly completely infected by 5 days after inoculum addition. Continuous exposure to -y-IFN (at concentrations greater than 25 IU/ml) resulted in almost complete inhibition of chlamydial infection. In contrast, preinfection treatment of y-IFN resulted in the progression of chlamydial infection (Fig. 2) . The lower the preinfection -y-IFN concentration was, the less time it took for the chlamydial infection to overcome the inhibitory effect of the IFN. At an IFN preinfection treatment of 25 IU/ml, the inhibitory effect of IFN was completely overcome within 48 h of infection. After preinfection treatment with 100 or 200 IU/ml, the inhibition was overcome to the extent of 40% chlamydial production only after 96 to 120 h. At a 400 IU/ml concentration of -y-IFN preinfection treatment, there was no sign of chlamydial production through 120 h.
To were only damaged forms of C. trachomatis (Fig. 3) . At an IFN dose effecting almost complete C. trachomatis inhibition (70 IU/ml), the developmental cycle of the C. trachomatis had reached at 48 h only the stage of RB formation (Fig.  4C) ; in IFN 50% effective dose treatment (14.5 IU/ml), the developmental cycle reached the formation of EBs as well (Fig. 4B) . But in contrast to the control (Fig. 4A) , in which the ratio of EBs to RBs was 3:1, in the IFN 50% effective dose treatment there were three times more RBs than EBs. Thus, the IFN concentration seems to be able to modulate C. trachomatis replication, which may indicate a possible role for IFN in the maintenance of chronic C. trachomatis infection in vivo (3, 7, 15a) 
